These features nominated GLP-1 agonists as a promising candidate for the treatment of neurodegenerative diseases including PD (Gilman et al. 2003; Perry et al. 2003; Perry et al. 2002a, b; Perry et al. 2002a, b). Here, GLP1R is linked to Parkinson disease.